MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income
$316,889K
Acquired in-process
research and development...
$284,887K
Amortization of intangible
assets
$76,662K
Share-based compensation
$51,565K
Impairment of intangible
asset
$48,700K
Depreciation and
amortization
$11,389K
Amortization of debt discount
$7,506K
Accounts payable and
accrued expenses
$6,211K
Induced conversion
expense related to 2027...
$5,477K
Loss on disposal of
equipment
-$2,621K
Inventories
-$2,554K
Lease payments
recognized (deferred)
-$951K
Deferred income taxes
-$634K
Net cash provided by
operating activities
$651,558K
Canceled cashflow
$164,488K
Net increase
(decrease) in cash, cash...
$20,571K
Canceled cashflow
$630,987K
Accounts receivable, net
and other contract...
$128,063K
Prepaid expenses and
other assets
$32,958K
Accretion of premium on
marketable securities, net
$3,296K
Realized gain on
marketable securities
$171K
Proceeds from sales and
maturities of marketable...
$722,248K
Proceeds from
convertible...
$735,000K
Proceeds from
convertible...
$735,000K
Proceeds from issuance of
common stock under...
$21,829K
Net cash used in
investing activities
-$545,813K
Net cash used in
financing activities
-$85,174K
Canceled cashflow
$722,248K
Canceled cashflow
$1,491,829K
Acquisition of business, net
of cash acquired
$725,965K
Repayments of convertible
notes-A0.25Convertible Senior Notes...
$595,425K
Acquisition of in-process
research and...
$287,771K
Purchases of marketable
securities
$247,355K
Purchases of property and
equipment
$6,970K
Repurchase of common stock
$342,372K
Repayments of convertible
notes-A1.00Convertible Senior Notes...
$250,001K
Purchase of capped calls
on 2031...
$106,800K
Purchase of capped calls
on 2031...
$104,025K
Premium on repayment of
convertible notes settled in...
$89,833K
Premium on repayment of
convertible notes settled in...
$78,132K
Payment for the induced
conversion of 2027 and 2028...
$5,477K
Payment of debt issuance
cost
$4,938K
Back
Back
Cash Flow
source: myfinsight.com
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)